apg777
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 29, 2024 (NCT06395948)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-13INHIBITOR
IL13 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07027527 | Phase 1 | Jun 4, 2025 | Apogee Therapeutics, Inc. |
| NCT07003425 | Phase 2 | May 14, 2025 | Apogee Therapeutics, Inc. |
| NCT06920901 | Phase 1 | Mar 27, 2025 | Apogee Therapeutics, Inc. |
| NCT06395948 | Phase 2 | Apr 29, 2024 | Apogee Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2024 |
1 organizations
Page 1 / 1